Association between dementia and vascular disease-associated polymorphisms in a Tunisian population

References

• Ramos AR, Dib SI, Wright CB. Vascular Dementia. Curr Transl Geriatr Exp Gerontol Rep 2013;2(3):188–195. PubMed PMID: 26213642; PubMed Central PMCID: PMCPmc4513364. Eng.
   PubMedGoogle Scholar
• Mahley RW, Rall SC, Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genom Hum Genet 2000;1:507–37. PubMed PMID: 11701639; eng.
   PubMed Web of Science ®Google Scholar
• Bagyinszky E, Youn YC, An SS, et al. The genetics of Alzheimer's disease. Clin Interv Aging 2014;9:535–551. PubMed PMID: 24729694; PubMed Central PMCID: PMCPmc3979693. Eng.
   PubMed Web of Science ®Google Scholar
• Baudin B. New aspects on angiotensin-converting enzyme: from gene to disease. Clin Chem Lab Med 2002;40(3):256–65. PubMed PMID: 12005216; eng.
   PubMed Web of Science ®Google Scholar
• Richard F, Berr C, Amant C, et al. Effect of the angiotensin I-converting enzyme I/D polymorphism on cognitive decline. Neurobiol Aging 2000;21(1):75–80. PubMed PMID: 10794851; eng.
   PubMed Web of Science ®Google Scholar
• Marsillach J, Mackness B, Mackness M, et al. Immunohistochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues. Free Radic Biol Med 2008;45(2):146–57. PubMed PMID: 18440321; eng.
   PubMed Web of Science ®Google Scholar
• Wingo TS, Rosen A, Cutler DJ, et al. Paraoxonase-1 polymorphisms in Alzheimer's disease, Parkinson's disease, and AD-PD spectrum diseases. Neurobiol Aging 2012;33(1):204.e13–5. PubMed PMID: 20947215; PubMed Central PMCID: PMCPmc3021799. eng.
   Web of Science ®Google Scholar
• She ZG, Chen HZ, Yan Y, et al. The human paraoxonase gene cluster as a target in the treatment of atherosclerosis. Antioxid Redox Signal 2012;16(6):597–632. PubMed PMID: 21867409; PubMed Central PMCID: PMCPmc3270057. eng.
   PubMed Web of Science ®Google Scholar
• Jaouad L, Milochevitch C, Khalil A. PON1 paraoxonase activity is reduced during HDL oxidation and is an indicator of HDL antioxidant capacity. Free Radic Res 2003;37(1):77–83. PubMed PMID: 12653220; eng.
   PubMed Web of Science ®Google Scholar
• Florentin M, Liberopoulos EN, Wierzbicki AS, et al. Multiple actions of high-density lipoprotein. Curr Opin Cardiol 2008;23(4):370–8. PubMed PMID: 18520722; eng.
   PubMed Web of Science ®Google Scholar
• McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease report of the NINCDS‐ADRDA Work Group* under the auspices of Department of health and human services Task Force on Alzheimer's disease. Neurology 1984;34(7):939–9.
   PubMed Web of Science ®Google Scholar
• Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucl Acids Res 1988;16(3):1215. PubMed PMID: 3344216; PubMed Central PMCID: PMCPmc334765. eng.
   PubMed Web of Science ®Google Scholar
• Rejeb J, Omezzine A, Rebhi L, et al. Association of PON1 and PON2 polymorphisms with PON1 activity and significant coronary stenosis in a Tunisian population. Biochem Genet 2013;51(1–2):76–91. PubMed PMID: 23053877.
   PubMed Web of Science ®Google Scholar
• Lindpaintner K, Pfeffer MA, Kreutz R, et al. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 1995;332(11):706–11. PubMed PMID: 7854377; eng.
   PubMed Web of Science ®Google Scholar
• Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31(3):545–8. PubMed PMID: 2341813; eng.
   PubMed Web of Science ®Google Scholar
• Boyle AP, Hong EL, Hariharan M, et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res 2012;22(9):1790–97.
   PubMed Web of Science ®Google Scholar
• Chang T-H, Huang H-Y, Hsu JB-K, et al. An enhanced computational platform for investigating the roles of regulatory RNA and for identifying functional RNA motifs. BMC Bioinform 2013;14(2):S4.
   PubMed Web of Science ®Google Scholar
• Crean S, Ward A, Mercaldi CJ, et al. Apolipoprotein E epsilon4 prevalence in Alzheimer's disease patients varies across global populations: a systematic literature review and meta-analysis. Dement Geriatr Cogn Disord 2011;31(1):20–30. PubMed PMID: 21124030; eng.
   PubMed Web of Science ®Google Scholar
• Liu X, Li L, Liu F, et al. ApoE gene polymorphism and vascular dementia in Chinese population: a meta-analysis. J Neural Transm 2012;119(3):387–94. PubMed PMID: 21984189; eng.
   PubMed Web of Science ®Google Scholar
• Tsuang D, Leverenz JB, Lopez OL, et al. APOE epsilon4 increases risk for dementia in pure synucleinopathies. JAMA Neurol 2013;70(2):223–8. PubMed PMID: 23407718; PubMed Central PMCID: PMCPmc3580799. eng.
   PubMed Web of Science ®Google Scholar
• Rassas AA, Mrabet Khiari H, Hadj Fredj S, et al. High APOE epsilon 4 allele frequencies associated with Alzheimer disease in a Tunisian population. Neurol Sci 2012;33(1):33–7. PubMed PMID: 21710128; eng.
   PubMed Web of Science ®Google Scholar
• Yu L, Boyle P, Schneider JA, et al. APOE epsilon4, Alzheimer's disease pathology, cerebrovascular disease, and cognitive change over the years prior to death. Psychol Aging 2013;28(4):1015–23. PubMed PMID: 23647000; PubMed Central PMCID: PMCPmc3766432. eng.
   PubMed Web of Science ®Google Scholar
• Beyer K, Lao JI, Fernandez-Novoa L, et al. APOE epsilon 4 allele frequency in Alzheimer's disease and vascular dementia in the Spanish population. Ann NY Acad Sci 1997;826:452–5. PubMed PMID: 9329722; eng.
   PubMed Web of Science ®Google Scholar
• Liu X, Li L, Liu F, et al. ApoE gene polymorphism and vascular dementia in Chinese population: a meta-analysis. J Neural Transm 2012;119(3):387–94. PubMed PMID: 21984189; eng.
   PubMed Web of Science ®Google Scholar
• Huang W, Qiu C, von Strauss E, et al. APOE genotype, family history of dementia, and Alzheimer disease risk: a 6-year follow-up study. Arch Neurol. 2004;61(12):1930–4. PubMed PMID: 15596614; eng.
   PubMedGoogle Scholar
• Mehta SG, Watts GD, Adamson JL, et al. APOE is a potential modifier gene in an autosomal dominant form of frontotemporal dementia (IBMPFD). Genet Med 2007;9(1):9–13.
   PubMed Web of Science ®Google Scholar
• Laws SM, Clarnette RM, Taddei K, et al. APOE-epsilon4 and APOE -491A polymorphisms in individuals with subjective memory loss. Mol Psychiatry 2002;7(7):768–75. PubMed PMID: 12192621.
   PubMed Web of Science ®Google Scholar
• Liu CC, Kanekiyo T, Xu H, et al. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 2013;9(2):106–18. PubMed PMID: 23296339; PubMed Central PMCID: PMCPmc3726719. eng.
   PubMed Web of Science ®Google Scholar
• Kawamata J, Tanaka S, Shimohama S, et al. Apolipoprotein E polymorphism in Japanese patients with Alzheimer's disease or vascular dementia. J Neurol Neurosurg Psychiat 1994;57(11):1414–6. PubMed PMID: 7964823; PubMed Central PMCID: PMCPmc1073199. eng.
   PubMed Web of Science ®Google Scholar
• Huang HM, Kuo YM, Ou HC, et al. Apolipoprotein E polymorphism in various dementias in Taiwan Chinese population. J Neural Transm 2002;109(11):1415–21. PubMed PMID: 12454737; eng.
   PubMed Web of Science ®Google Scholar
• Ohm TG, Kirca M, Bohl J, et al. Apolipoprotein E polymorphism influences not only cerebral senile plaque load but also Alzheimer-type neurofibrillary tangle formation. Neuroscience 1995;66(3):583–7. PubMed PMID: 7644022; eng.
   PubMed Web of Science ®Google Scholar
• Palumbo B, Parnetti L, Nocentini G, et al. Apolipoprotein-E genotype in normal aging, age-associated memory impairment, Alzheimer's disease and vascular dementia patients. Neurosci Lett 1997;231(1):59–61. PubMed PMID: 9280168; eng.
   PubMed Web of Science ®Google Scholar
• Wang HK, Fung HC, Hsu WC, et al. Apolipoprotein E, angiotensin-converting enzyme and kallikrein gene polymorphisms and the risk of Alzheimer's disease and vascular dementia. J Neural Transm 2006;113(10):1499–509. PubMed PMID: 16465461.
   PubMed Web of Science ®Google Scholar
• Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci U S A 2006;103(15):5644–51. PubMed PMID: 16567625; PubMed Central PMCID: PMCPmc1414631. eng.
   PubMed Web of Science ®Google Scholar
• Ye S, Huang Y, Mullendorff K, et al. Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. Proc Natl Acad Sci U S A 2005;102(51):18700–5. PubMed PMID: 16344478; PubMed Central PMCID: PMCPmc1311738. eng.
   PubMed Web of Science ®Google Scholar
• Kanekiyo T, Xu H, Bu G. ApoE and Abeta in Alzheimer's disease: accidental encounters or partners? Neuron 2014;81(4):740–54. PubMed PMID: 24559670; PubMed Central PMCID: PMC3983361.
   PubMed Web of Science ®Google Scholar
• Holtzman DM, Herz J, Bu G. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med 2012;2(3):a006312. PubMed PMID: 22393530; PubMed Central PMCID: PMCPmc3282491. eng.
   PubMed Web of Science ®Google Scholar
• Kölsch H, Jessen F, Freymann N, et al. ACE I/D polymorphism is a risk factor of Alzheimer's disease but not of vascular dementia. Neurosci Lett 2005;377(1):37–9. PubMed PMID: 15722183; eng.
   PubMed Web of Science ®Google Scholar
• Lehmann DJ, Cortina-Borja M, Warden DR, et al. Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer's disease. Am J Epidemiol 2005;162(4):305–17. PubMed PMID: 16033878.
   PubMed Web of Science ®Google Scholar
• Lucatelli JF, Barros AC, Silva VK, et al. Genetic influences on Alzheimer's disease: evidence of interactions between the genes APOE, APOC1 and ACE in a sample population from the South of Brazil. Neurochem Res 2011;36(8):1533–9. PubMed PMID: 21533863; eng.
   PubMed Web of Science ®Google Scholar
• Wang XB, Cui NH, Yang J, et al. Angiotensin-converting enzyme insertion/deletion polymorphism is not a major determining factor in the development of sporadic Alzheimer disease: evidence from an updated meta-analysis. PLoS One 2014;9(10):e111406. PubMed PMID: 25360660; PubMed Central PMCID: PMCPMC4216072. eng.
   PubMed Web of Science ®Google Scholar
• Yang L, Zhou HH, Ye YF, et al. Association of PS1 1/2, ACE I/D, and LRP C/T polymorphisms with Alzheimer's disease in the Chinese population: a meta-analysis of case-control studies. Genet Mol Res 2015;14(1):1017–24. PubMed PMID: 25730041; eng.
   PubMed Web of Science ®Google Scholar
• Narain Y, Yip A, Murphy T, et al. The ACE gene and Alzheimer's disease susceptibility. J Med Genet 2000;37(9):695–7. PubMed PMID: 10978362; PubMed Central PMCID: PMCPmc1734696. eng.
   PubMed Web of Science ®Google Scholar
• Wang B, Jin F, Yang Z, et al. The insertion polymorphism in angiotensin-converting enzyme gene associated with the APOE epsilon 4 allele increases the risk of late-onset Alzheimer disease. J Mol Neurosci 2006;30(3):267–71. PubMed PMID: 17401152; eng.
   PubMed Web of Science ®Google Scholar
• Sahin S, Ceyhan K, Benli I, et al. Traditional risk factors and angiotensin-converting enzyme insertion/deletion gene polymorphism in coronary artery disease. Genet Mol Res 2015;14(1):2063–8. PubMed PMID: 25867352; eng.
   PubMed Web of Science ®Google Scholar
• Miners JS, Baig S, Palmer J, et al. Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol 2008;18(2):240–52. PubMed PMID: 18363935; eng.
   PubMed Web of Science ®Google Scholar
• Hemming ML, Selkoe DJ. Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem 2005;280(45):37644–50. PubMed PMID: 16154999; PubMed Central PMCID: PMCPmc2409196. eng.
   PubMed Web of Science ®Google Scholar
• Zou K, Yamaguchi H, Akatsu H, et al. Angiotensin-converting enzyme converts amyloid beta-protein 1-42 (Abeta(1-42)) to Abeta(1-40), and its inhibition enhances brain Abeta deposition. J Neurosci 2007;27(32):8628–35. PubMed PMID: 17687040; eng.
   PubMed Web of Science ®Google Scholar
• Hu J, Igarashi A, Kamata M, et al. Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem 2001;276(51):47863–8. PubMed PMID: 11604391.
   PubMed Web of Science ®Google Scholar
• Wright JW, Harding JW. Brain renin-angiotensin–a new look at an old system. Prog Neurobiol 2011;95(1):49–67. PubMed PMID: 21777652; eng.
   PubMed Web of Science ®Google Scholar
• Kehoe PG, Wilcock GK. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease? Lancet Neurol 2007;6(4):373–8. PubMed PMID: 17362841; eng.
   PubMed Web of Science ®Google Scholar
• Katzov H, Bennet AM, Kehoe P, et al. A cladistic model of ACE sequence variation with implications for myocardial infarction, Alzheimer disease and obesity. Hum Mol Genet 2004;13(21):2647–57. PubMed PMID: 15367486; eng.
   PubMed Web of Science ®Google Scholar
• Goossens GH, Blaak EE, van Baak MA. Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. Obes Rev 2003;4(1):43–55. PubMed PMID: 12608526; eng.
   PubMedGoogle Scholar
• Wright JW, Kawas LH, Harding JW. The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases. Prog Neurobiol 2015;125:26–46. PubMed PMID: 25455861; eng.
   PubMed Web of Science ®Google Scholar
• Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier. Nat Med 2013;19(12):1584–96.
   PubMed Web of Science ®Google Scholar
• Wosik K, Cayrol R, Dodelet-Devillers A, et al. Angiotensin II controls occludin function and is required for blood–brain barrier maintenance: relevance to multiple sclerosis. J Neurosci 2007;27(34):9032–42.
   PubMed Web of Science ®Google Scholar
• Wright JW, Kawas LH, Harding JW. A role for the brain RAS in Alzheimer's and Parkinson's diseases. Front Endocrinol (Lausanne) 2013;4:158. PubMed PMID: 24298267; PubMed Central PMCID: PMCPmc3829467. eng.
   PubMedGoogle Scholar
• Leduc V, Poirier J. Polymorphisms at the paraoxonase 1 L55M and Q192R loci affect the pathophysiology of Alzheimer's disease: emphasis on the cholinergic system and beta-amyloid levels. Neurodegener Dis 2008;5(3–4):225–7. PubMed PMID: 18322397; eng.
   PubMed Web of Science ®Google Scholar
• He XM, Zhang ZX, Zhang JW, et al. Gln192Arg polymorphism in paraoxonase 1 gene is associated with Alzheimer disease in a Chinese Han ethnic population. Chin Med J (Engl) 2006;119(14):1204–9. PubMed PMID: 16863614; eng.
   PubMed Web of Science ®Google Scholar
• Chapuis J, Boscher M, Bensemain F, et al. Association study of the paraoxonase 1 gene with the risk of developing Alzheimer's disease. Neurobiol Aging 2009;30(1):152–6. PubMed PMID: 17624629; eng.
   PubMed Web of Science ®Google Scholar
• Pi Y, Zhang L, Chang K, et al. Lack of an association between Paraoxonase 1 gene polymorphisms (Q192R, L55M) and Alzheimer's disease: a meta-analysis. Neurosci Lett 2012;523(2):174–9. PubMed PMID: 22776645; eng.
   PubMed Web of Science ®Google Scholar
• Wingo TS, Rosen A, Cutler DJ, et al. Paraoxonase 1 polymorphisms in Alzheimer's disease, Parkinson's disease, and AD-PD spectrum diseases. Neurobiol Aging 2012;33(1):204.e13–204.e15. PubMed PMID: PMC3021799.
   Web of Science ®Google Scholar
• Androutsopoulos VP, Kanavouras K, Tsatsakis AM. Role of paraoxonase 1 (PON1) in organophosphate metabolism: implications in neurodegenerative diseases. Toxicol Appl Pharmacol 2011;256(3):418–24. PubMed PMID: 21864557; eng.
   PubMed Web of Science ®Google Scholar
• Dantoine TF, Drouet M, Debord J, et al. Paraoxonase 1 192/55 gene polymorphisms in Alzheimer's disease. Ann N Y Acad Sci 2002;977:239–44. PubMed PMID: 12480756; eng.
   PubMed Web of Science ®Google Scholar
• Erlich PM, Lunetta KL, Cupples LA, et al. Serum paraoxonase activity is associated with variants in the PON gene cluster and risk of Alzheimer disease. Neurobiol Aging 2012;33(5):1015.e7–23. PubMed PMID: 20980077; PubMed Central PMCID: PMCPmc3034817. eng.
   Web of Science ®Google Scholar
• Komoda T. The HDL handbook: biological functions and clinical implications. New York, NY: Academic Press; 2013. p. 102–104.
   Google Scholar
• Wehr H, Bednarska-Makaruk M, Graban A, et al. Paraoxonase activity and dementia. J Neurol Sci 2009;283(1–2):107–8. PubMed PMID: 19268306; eng.
   PubMed Web of Science ®Google Scholar
• Pola R, Flex A, Ciaburri M, et al. Responsiveness to cholinesterase inhibitors in Alzheimer's disease: a possible role for the 192 Q/R polymorphism of the PON-1 gene. Neurosci Lett 2005;382(3):338–41. PubMed PMID: 15925115; eng.
   PubMed Web of Science ®Google Scholar
• Villard E, Tiret L, Visvikis S, et al. Identification of new polymorphisms of the angiotensin I-converting enzyme (ACE) gene, and study of their relationship to plasma ACE levels by two-QTL segregation-linkage analysis. Am J Hum Genet 1996;58(6):1268–78. PubMed PMID: 8651305; PubMed Central PMCID: PMCPmc1915072. eng.
   PubMed Web of Science ®Google Scholar
• McKenzie CA, Sinsheimer JS, Adeyemo AA, et al. SNP haplotypes in the angiotensin I-converting enzyme (ACE) gene: analysis of Nigerian family data using gamete competition models. Ann Hum Genet 2005;69(Pt 2):227–32. PubMed PMID: 15720304; eng.
   PubMed Web of Science ®Google Scholar
• Cox R, Bouzekri N, Martin S, et al. Angiotensin-1-converting enzyme (ACE) plasma concentration is influenced by multiple ACE-linked quantitative trait nucleotides. Hum Mol Genet 2002;11(23):2969–77. PubMed PMID: 12393808; eng.
   PubMed Web of Science ®Google Scholar
• Ong C-T, Corces VG. CTCF: an architectural protein bridging genome topology and function [Review]. Nat Rev Genet 2014; 15(4):234–46.
   PubMed Web of Science ®Google Scholar
• Ohlsson R, Renkawitz R, Lobanenkov V. CTCF is a uniquely versatile transcription regulator linked to epigenetics and disease. Trends Genet 2001;17(9):520–7. PubMed PMID: 11525835; eng.
   PubMed Web of Science ®Google Scholar
• Phillips JE, Corces VG. CTCF: master weaver of the genome. Cell 2009;137(7):1194–211. PubMed PMID: 19563753; PubMed Central PMCID: PMCPmc3040116. eng.
   PubMed Web of Science ®Google Scholar
• Ziebarth JD, Bhattacharya A, Cui Y. CTCFBSDB 2.0: a database for CTCF-binding sites and genome organization. Nucleic Acids Res 2013;41(D1):D188–D194.
   PubMed Web of Science ®Google Scholar
• Li T, Hu J-F, Qiu X, et al. CTCF Regulates allelic expression of Igf2 by orchestrating a promoter-polycomb repressive complex 2 intrachromosomal loop. Mol Cell Biol 2008;28(20):6473–82.
   PubMed Web of Science ®Google Scholar
• Li H-B, Ohno K, Gui H, et al. Insulators target active genes to transcription factories and polycomb-repressed genes to polycomb bodies. PLoS Genet 2013;9(4):e1003436.
   PubMed Web of Science ®Google Scholar
• Szabó PE, Tang S-HE, Rentsendorj A, et al. Maternal-specific footprints at putative CTCF sites in the H19 imprinting control region give evidence for insulator function. Curr Biol 2000;10(10):607–10.
   PubMed Web of Science ®Google Scholar
• Tilghman AT, Schoenherr CJ, Katz DJ, et al. CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature 2000;405(6785):486–9.
   PubMed Web of Science ®Google Scholar
• Felsenfeld AC, Felsenfeld G. Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene. Nature. 2000;405(6785):482–5.
   PubMed Web of Science ®Google Scholar
• Dorsett D. Cohesin: genomic insights into controlling gene transcription and development. Curr Opin Genet Dev 2011;21(2):199–206.
   PubMed Web of Science ®Google Scholar
• Wallace JA, Felsenfeld G. We gather together: insulators and genome organization. Curr Opin Genet Dev 2007;17(5):400–407.
   PubMed Web of Science ®Google Scholar
• Nativio R, Wendt KS, Ito Y, et al. Cohesin is required for higher-order chromatin conformation at the imprinted IGF2-H19 locus. PLoS Genet 2009;5(11):e1000739–e1000739.
   PubMed Web of Science ®Google Scholar
• Di Croce L, Helin K. Transcriptional regulation by Polycomb group proteins [Review]. Nat Struct Mol Biol 2013;20(10):1147–55.
   PubMed Web of Science ®Google Scholar
• Kohlstedt K, Trouvain C, Boettger T, et al. AMP-activated protein kinase regulates endothelial cell angiotensin-converting enzyme expression via p53 and the post-transcriptional regulation of microRNA-143/145. Circ Res 2013;112(8):1150–8. PubMed PMID: 23476055; eng.
   PubMed Web of Science ®Google Scholar